美国真实世界中接受特立帕肽治疗患者髋部及其他脆性骨折发生率
基于Truven MarketScan数据库2004至2014年数据,纳入14,284例≥18岁特立帕肽使用者,随访用药前12个月及用药后24个月。 adherence和持续性越高,任何临床骨折、椎体骨折、非椎体骨折及髋部骨折发生率均显著降低,腕部骨折除外。
要点
- 高依从性(MPR≥0.80)较低依从性(MPR<0.50)与任何骨折(OR=0.67)、椎体骨折(OR=0.64)、非椎体骨折(OR=0.71)、髋部骨折(OR=0.52)风险降低相关,均P<.001。
- 持续性19-24个月较1-6个月与任何骨折(OR=0.63)、椎体骨折(OR=0.56)、非椎体骨折(OR=0.69)、髋部骨折(OR=0.48)风险降低相关,均P<.001。
- Cox模型显示高依从性较低依从性显著降低任何骨折(OR=0.69)、椎体骨折(OR=0.60)、非椎体骨折(OR=0.77)、髋部骨折(OR=0.55)风险,均P<.001。
核心结论
- 随着特立帕肽持续性和依从性增加,骨折发生率显著下降。
研究设计与样本
- 基于Truven MarketScan研究数据库2004年至2014年数据,纳入≥18岁特立帕肽使用者,要求用药前12个月及用药后24个月连续覆盖。
- 依从性按药物持有率(MPR)分为高(≥0.80)、中(0.50≤MPR<0.80)、低(<0.50)三组。
- 持续性允许处方间≤90天间隔,分为1-6、7-12、13-18、19-24个月四组。
主要发现
- 共纳入14,284例特立帕肽使用者,平均年龄68.4岁,女性占89.8%,29.6%既往一年内有骨折。
- 除腕部骨折(P≥.125)外,依从性和持续性对各类骨折的影响均有统计学意义(P<.001)。
- 逻辑回归显示高依从性较低依从性降低任何骨折(OR=0.67)、椎体骨折(OR=0.64)、非椎体骨折(OR=0.71)、髋部骨折(OR=0.52)风险,均P<.001。
- 逻辑回归显示持续性19-24个月较1-6个月降低任何骨折(OR=0.63)、椎体骨折(OR=0.56)、非椎体骨折(OR=0.69)、髋部骨折(OR=0.48)风险,均P<.001。
- Cox模型显示高依从性较低依从性降低任何骨折(OR=0.69)、椎体骨折(OR=0.60)、非椎体骨折(OR=0.77)、髋部骨折(OR=0.55)风险,均P<.001。
关键数值与推荐
- 依从性分组:高MPR≥0.80,中0.50≤MPR<0.80,低MPR<0.50。
- 持续性分组:1-6、7-12、13-18、19-24个月,允许处方间≤90天间隔。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study demonstrates real-world effectiveness of teriparatide in reducing the risk of hip and other fragility fractures. Fracture incidence significantly decreased as adherence and persistence increased for any clinical, vertebral, nonvertebral, and hip fractures among patients who were observed for 2 years after teriparatide initiation. INTRODUCTION: Examine the relationship of treatment adherence and persistence to teriparatide with hip and other fractures. METHODS: Truven MarketScan Research Databases, 2004 through 2014, provided teriparatide users ≥18 years old with continuous coverage 12 months pre- and 24 months post-teriparatide prescription. Adherence (medication possession ratio, MPR) groups were defined as high (≥0.80), medium (0.50 ≤ MPR < 0.80), and low (<0.50). Persistence, allowing for ≤90-day gaps between prescriptions, was defined as 1-6, 7-12, 13-18, and 19-24 months. Fracture incidence was summarized and compared by using ANOVA and logistic regression models; the effects of adherence were examined with Cox proportional hazard models with time-dependent covariates for teriparatide exposure. RESULTS: Among 14,284 teriparatide subjects, mean age was 68.4 years, 89.8% were female, and 29.6% had a fracture in the previous year; these characteristics were similar across MPR and persistence groups. The effects of adherence and persistence to teriparatide were statistically significant (P < .001) for all fracture types except wrist (P ≥ .125). By logistic regression, high vs low adherence was associated with reduced risk for any (OR = 0.67; P < .001); vertebral (OR = 0.64; P < .001); nonvertebral (OR = 0.71; P < .001); and hip fractures (OR = 0.52; P < .001) and longer (19-24 months) vs shorter persistence (1-6 months) was associated with reduced risk for any (OR = 0.63, P < .001); vertebral (OR = 0.56, P < .001); nonvertebral (OR = 0.69, P < .001); and hip fractures (OR = 0.48, P < .001). Cox models revealed a significantly reduced risk between high and low adherence for any (OR = 0.69, P < .001); vertebral (OR = 0.60, P < .001); nonvertebral (OR = 0.77, P < .001); and hip fractures (OR = 0.55, P < .001). CONCLUSION: Fracture incidence significantly decreased as persistence and adherence to teriparatide increased.
引用
- Burge RT, Disch DP, Gelwicks S, et al. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States. Osteoporos Int. 2016. PMID: 28028555. doi:10.1007/s00198-016-3888-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。